Previous 10 | Next 10 |
Libtayo-based combination demonstrated superior survival outcomes compared to chemotherapy alone in Phase 3 trial designed to include patients with varied disease presentations seen in everyday clinical practice Approval marks second first-line indication in NSCLC and fifth indication f...
2023-03-29 05:26:13 ET U.K.'s National Institute for Clinical Excellence (NICE) in its final draft guidance recommended Amgen ( NASDAQ: AMGN ) and AstraZeneca's ( NASDAQ: AZN ) asthma therapy Tezspire for use in the National Health Service (NHS). The drug p...
2023-03-28 08:52:07 ET Sonoma Biotherapeutics and Regeneron Pharmaceuticals ( NASDAQ: REGN ) signed an agreement to discover, develop and sell novel regulatory T cell (T reg ) therapies for autoimmune diseases. Under the agreement, Sonoma will get $75M upfront, which inc...
TARRYTOWN, N.Y., and SOUTH SAN FRANCISCO, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sonoma Biotherapeutics, Inc. today announced a collaboration to apply their scientific and clinical expertise and respective technology platforms ...
Sonoma Biotherapeutics to receive $75 million upfront, inclusive of $45 million cash and $30 million equity investment; potential for an additional $45 million development milestone payment Sonoma Biotherapeutics, Inc. and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today ann...
2023-03-27 08:32:38 ET Unity Biotechnology ( NASDAQ: UBX ) lost ~48% pre-market Monday after announcing that its lead candidate UBX1325 failed to outperform Regeneron’s ( REGN ) blockbuster eye therapy aflibercept in a Phase 2 trial for wet age-related macular deg...
2023-03-25 08:43:00 ET Recently, Sanofi (NASDAQ: SNY) and Regeneron (NASDAQ: REGN) received positive news from the U.S. Food and Drug Administration (FDA). The agency accepted Dupixent's supplemental Biologics License Application for review to treat adult patients with chron...
2023-03-25 06:54:15 ET Summary Regeneron stock hit a record high on March 24, 2023. Dupixent COPD data was reported as positive. Concerns about Eylea competition remain, so I am neutral on REGN stock. For further details see: Regeneron Pharmaceuticals...
2023-03-24 12:02:33 ET The stock market started out on an uncertain note on Friday, initially falling but cutting its losses in the first hour of the trading day. The S&P 500 (SNPINDEX: ^GSPC) was down about 0.4% as of 10:30 a.m. ET, and investors appeared to be a little wary of...
2023-03-24 08:44:10 ET Regeneron ( NASDAQ: REGN ) continued to earn bullish views on Wall Street after the company, and its partner Sanofi ( SNY ) announced that asthma therapy Dupixent succeeded in a Phase 3 trial for adult smokers with chronic obstructive pulmonary disea...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...